BACKGROUND OBJECTIVES

DISCUSSION
Conventional treatment for chronic hypoparathyroidism (CHP) is activated vitamin D analogues and calcium supplementation and not replacement of the lacking hormone, as done in other hormonal deficiency states.
Retrospective evaluation of CHP management in line with
European Society of Endocrinology guideline 1 was undertaken in a tertiary centre, to assess adequacy of calcium homeostasis and morbidity.
1. In our case series, conventional CHP management resulted in suboptimal calcium homeostasis in half of patients and more than 1/3 rd required hospital admissions for calcium regulation 2. Suboptimal monitoring of 24 hr urine calcium and magnesium was noted. 3. Regular monitoring of the biochemical parameters and adjustment of the medications may improve the outcome. 4. Evidence seems to be growing for recombinant human parathyroid hormone for challenging cases with labile calcium levels. 2 
